Cargando…
An Open-Label Rater-Blinded Randomized Trial of Vilazodone versus Escitalopram in Major Depression
BACKGROUND: Vilazodone, a novel selective serotonin reuptake inhibitor and 5-HT1A partial agonist, was approved in 2011 for treatment for major depression. We aimed to compare the efficacy and safety of vilazodone versus escitalopram in patients with major depression at 4 weeks. METHODS: Participant...
Autores principales: | Kumar, Pattath Narayanan Suresh, Suresh, Rohith, Menon, Vikas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896102/ https://www.ncbi.nlm.nih.gov/pubmed/36778613 http://dx.doi.org/10.1177/02537176221127162 |
Ejemplares similares
-
Escitalopram-induced extrapyramidal symptoms
por: Kumar, Pattath Narayanan Suresh, et al.
Publicado: (2019) -
An Interim Analysis of a Randomized, Open-Label Study of Vilazodone, Escitalopram, or Vortioxetine for Major Depressive Disorder
por: Santi, N Simple, et al.
Publicado: (2023) -
Comparative evaluation of efficacy and tolerability of vilazodone, escitalopram, and amitriptyline in patients of major depressive disorder: A randomized, parallel, open-label clinical study
por: Kadam, Renuka L., et al.
Publicado: (2020) -
Paroxetine versus Venlafaxine and Escitalopram in Korean Patients with Major Depressive Disorder: A Randomized, Rater-blinded, Six-week Study
por: Woo, Young Sup, et al.
Publicado: (2017) -
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Vilazodone in Adolescents with Major Depressive Disorder
por: Durgam, Suresh, et al.
Publicado: (2018)